Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Debt to Equity: 2021

  • ARS Pharmaceuticals' Debt to Equity was N/A to -$0.16 in Q4 2021 from the same period last year, while for Dec 2021 it was -$0.16, marking a year-over-year change of. This contributed to the annual value of -$0.16 for FY2021, which is N/A change from last year.
  • ARS Pharmaceuticals' Debt to Equity amounted to -$0.16 in Q4 2021, which was down 11,838.78% from $0.00 recorded in Q1 2021.
  • ARS Pharmaceuticals' Debt to Equity's 5-year high stood at $0.00 during Q1 2021, with a 5-year trough of -$0.16 in Q4 2021.
  • Over the past 1 years, ARS Pharmaceuticals' median Debt to Equity value was -$0.08 (recorded in 2021), while the average stood at -$0.08.